Trial Profile

A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 25 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Fluorouracil; Mitomycin
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Squamous cell cancer; Transitional cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms Rad-IO

Most Recent Events

02 Jun 2026 According to the Institute of Cancer Research Media Release, data from this study were presented at the American Society of Clinical Oncology (ASCO) annual meeting.
02 Jun 2026 Results presented in The Institute of Cancer Research Media Release.
20 Sep 2023 Planned End Date changed from 30 Apr 2028 to 30 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com